MA50752A - Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation - Google Patents

Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Info

Publication number
MA50752A
MA50752A MA050752A MA50752A MA50752A MA 50752 A MA50752 A MA 50752A MA 050752 A MA050752 A MA 050752A MA 50752 A MA50752 A MA 50752A MA 50752 A MA50752 A MA 50752A
Authority
MA
Morocco
Prior art keywords
methods
drug conjugates
antibody drug
activable antibody
antibodies
Prior art date
Application number
MA050752A
Other languages
English (en)
Other versions
MA50752B1 (fr
Inventor
Ilaria Badagnani
Sahana Bose
Tracy Henriques
Marvin Robert Leanna
Susan E Morgan-Lappe
Sherry L Ralston
Jennifer Hope Richardson
Laura Patterson Serwer
Shweta Singh
Jonathan Alexander Terrett
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MA50752A publication Critical patent/MA50752A/fr
Publication of MA50752B1 publication Critical patent/MA50752B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne d'une manière générale des anticorps qui se lient spécifiquement à cd71 dans leur forme active et des procédés de réalisation et d'utilisation de ces anticorps anti-cd711 activables conjugués dans une variété d'indications thérapeutiques, diagnostiques et prophylactiques.
MA50752A 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation MA50752B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
PCT/US2018/055733 WO2019075417A1 (fr) 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
MA50752A true MA50752A (fr) 2020-08-12
MA50752B1 MA50752B1 (fr) 2021-03-31

Family

ID=64110112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50752A MA50752B1 (fr) 2017-10-14 2018-10-12 Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation

Country Status (36)

Country Link
US (3) US20190111150A1 (fr)
EP (2) EP3691692B8 (fr)
JP (2) JP7374891B2 (fr)
KR (4) KR102385495B1 (fr)
CN (1) CN111278467B (fr)
AR (1) AR115178A1 (fr)
AU (1) AU2018346969A1 (fr)
BR (1) BR112020007302B1 (fr)
CA (1) CA3077730A1 (fr)
CL (1) CL2020000977A1 (fr)
CO (1) CO2020005685A2 (fr)
CR (1) CR20200206A (fr)
CY (1) CY1123968T1 (fr)
DK (1) DK3691692T3 (fr)
DO (1) DOP2023000150A (fr)
EC (1) ECSP20025198A (fr)
ES (1) ES2864013T3 (fr)
HR (1) HRP20210436T8 (fr)
HU (1) HUE054037T2 (fr)
IL (1) IL273586A (fr)
LT (1) LT3691692T (fr)
MA (1) MA50752B1 (fr)
MD (1) MD3691692T2 (fr)
MX (1) MX2020003723A (fr)
PE (1) PE20210125A1 (fr)
PH (1) PH12020550417A1 (fr)
PL (1) PL3691692T3 (fr)
PT (1) PT3691692T (fr)
RS (1) RS61596B1 (fr)
RU (2) RU2022111211A (fr)
SG (1) SG11202003378WA (fr)
SI (1) SI3691692T1 (fr)
SM (1) SMT202100184T1 (fr)
TW (2) TWI780237B (fr)
UY (1) UY37931A (fr)
WO (1) WO2019075417A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
IL310251A (en) * 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
ES3065816T3 (en) 2017-06-07 2026-05-08 Regeneron Pharma Compositions and methods for internalizing enzymes
BR112020007302B1 (pt) * 2017-10-14 2023-01-31 Abbvie Inc. Anticorpos ativáveis conjugados anti-cd71, método para fabrica-los, composição farmacêutica e kit que compreende os mesmos, usos dos ditos anticorpos, bem como método in vitro para detectar a presença ou ausência do agente de clivagem na amostra
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
WO2019183633A1 (fr) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Composés conjugués ciblés sur le psma et leurs utilisations
BR112020023145A2 (pt) 2018-05-17 2021-02-02 Regeneron Pharmaceuticals, Inc. anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
EP4132589A4 (fr) * 2020-04-08 2024-05-08 Aliada Therapeutics, Inc. Compositions et méthodes d'administration à la barrière hémato-encéphalique
CA3174665A1 (fr) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions contenant des anticorps activables
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US20240382513A1 (en) * 2021-07-09 2024-11-21 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
CA3237590A1 (fr) 2021-11-09 2023-05-08 James Basilion Composes conjugues cibles sur psma et leurs utilisations
KR20250054842A (ko) * 2022-07-29 2025-04-23 리제너론 파마슈티칼스 인코포레이티드 뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025133132A1 (fr) * 2023-12-20 2025-06-26 Institut National De La Sante Et De La Recherche Medicale Nouveaux anticorps anti-tfr1 (cd71) pour le traitement du cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP2535346B1 (fr) 2005-08-31 2017-08-02 The Regents of The University of California Bibliothèques cellulaires de séquences peptidiques (CliPS) et procédés d'utilisation de celles-ci
US20090304719A1 (en) 2007-08-22 2009-12-10 Patrick Daugherty Activatable binding polypeptides and methods of identification and use thereof
KR101811965B1 (ko) * 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
WO2010081173A2 (fr) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Compositions d’anticorps modifiées et leurs procédés de production et d’utilisation
JP5925116B2 (ja) * 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体
EP2427479B1 (fr) 2009-05-07 2018-11-21 The Regents of The University of California Anticorps et procédés d'utilisation de ceux-ci
EP2670440B1 (fr) * 2011-02-01 2018-09-05 Genmab A/S Anticorps humains et conjugués anticorps-médicament contre cd74
CN104284903B (zh) * 2012-01-31 2020-10-09 Sbi生物技术有限公司 抗磷脂酶d4抗体
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
IL310251A (en) 2015-05-04 2024-03-01 Cytomx Therapeutics Inc Anti-cd71 antibodies, activatable anti-cd71 antibodies, compositions comprising same and uses thereof
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用
BR112020007302B1 (pt) * 2017-10-14 2023-01-31 Abbvie Inc. Anticorpos ativáveis conjugados anti-cd71, método para fabrica-los, composição farmacêutica e kit que compreende os mesmos, usos dos ditos anticorpos, bem como método in vitro para detectar a presença ou ausência do agente de clivagem na amostra

Also Published As

Publication number Publication date
KR102529359B1 (ko) 2023-05-09
SI3691692T1 (sl) 2021-04-30
US20240115724A1 (en) 2024-04-11
DOP2023000150A (es) 2023-08-31
KR20200070324A (ko) 2020-06-17
PL3691692T3 (pl) 2021-07-19
AU2018346969A1 (en) 2020-04-23
MD3691692T2 (ro) 2021-05-31
RU2020115713A (ru) 2021-11-16
TW201927815A (zh) 2019-07-16
EP3691692A1 (fr) 2020-08-12
KR102385495B1 (ko) 2022-04-15
US20190111150A1 (en) 2019-04-18
KR20220045088A (ko) 2022-04-12
US20210145978A1 (en) 2021-05-20
HRP20210436T8 (hr) 2022-01-07
PE20210125A1 (es) 2021-01-19
CR20200206A (es) 2021-02-18
AR115178A1 (es) 2020-12-09
KR20230070046A (ko) 2023-05-19
HRP20210436T1 (hr) 2021-04-30
TWI780237B (zh) 2022-10-11
SMT202100184T1 (it) 2021-05-07
RS61596B1 (sr) 2021-04-29
EP3691692B1 (fr) 2020-12-30
PH12020550417A1 (en) 2021-04-12
CO2020005685A2 (es) 2020-05-15
EP3691692B8 (fr) 2021-05-26
JP2020537649A (ja) 2020-12-24
UY37931A (es) 2019-04-30
CN111278467B (zh) 2024-07-30
CN111278467A (zh) 2020-06-12
SG11202003378WA (en) 2020-05-28
MX2020003723A (es) 2020-07-22
CL2020000977A1 (es) 2020-09-11
ECSP20025198A (es) 2020-06-30
DK3691692T3 (da) 2021-03-22
RU2771292C2 (ru) 2022-04-29
LT3691692T (lt) 2021-05-10
WO2019075417A1 (fr) 2019-04-18
MA50752B1 (fr) 2021-03-31
KR20230004932A (ko) 2023-01-06
CY1123968T1 (el) 2022-05-27
IL273586A (en) 2020-05-31
HUE054037T2 (hu) 2021-08-30
PT3691692T (pt) 2021-03-29
RU2022111211A (ru) 2022-05-05
RU2020115713A3 (fr) 2022-02-25
JP2024012366A (ja) 2024-01-30
ES2864013T3 (es) 2021-10-13
BR112020007302A2 (pt) 2020-09-29
CA3077730A1 (fr) 2019-04-18
JP7374891B2 (ja) 2023-11-07
EP3834846A1 (fr) 2021-06-16
TW202330039A (zh) 2023-08-01
BR112020007302B1 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
MA50752B1 (fr) Conjugués de médicament anticorps activables anti-cd71 et leurs procédés d'utilisation
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
WO2019014328A3 (fr) Anticorps agonistes qui lient cd137 humain et leurs utilisations
MA32899B1 (fr) Combinaisons anticancereuses contenant des anticorps reconnaissant specifiquement cd38 et de la cytarabine
CR20120505A (es) Composición de fármaco conjugado
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
MA53330A (fr) Constructions d'anticorps pour cldn18.2 et cd3
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
EP3783025A4 (fr) Anticorps cd73 ciblé et conjugué anticorps-médicament, procédé de préparation associé et utilisations correspondantes
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
SA519401647B1 (ar) y مركبات ببتيد تيروسين-تيروسين الحلقية المقترنة بجسم مضاد كمعدلات لمستقبلات الببتيد العصبي
MA43345A (fr) Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
CR10273A (es) "anticuerpos anti-5t4 y usos de los mismos"
MA40671B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA31984B1 (fr) Formulation d'anticorps
CR8317A (es) Anticuerpos dirigidos a m-csf
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
ATE391174T1 (de) Modifizierter tpo-agonisten antikörper
JOP20190155A1 (ar) مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
MA31793B1 (fr) Nouveaux anticorps specifiques de peptides beta- amyloides et leurs utilisations comme agents diagnostiques ou medicaments